Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$135.78
+1.0%
$132.94
$99.71
$141.23
$236.66B0.736.12 million shs5.75 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$84.35
-3.4%
$82.12
$57.52
$117.19
$33.07B1.463.98 million shs20,950 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$783.79
+0.5%
$779.41
$677.09
$972.53
$742.82B0.413.87 million shs64,458 shs
Medtronic PLC stock logo
MDT
Medtronic
$87.07
-0.1%
$84.93
$75.96
$96.25
$111.67B0.797.79 million shs2,146 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$68.40
-0.9%
$69.32
$57.00
$143.69
$305.39B0.669.36 million shs123,058 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+1.26%+2.12%+1.80%+3.33%+30.97%
DexCom, Inc. stock logo
DXCM
DexCom
+1.11%+9.33%+1.55%+29.66%-23.01%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.41%+1.19%+5.56%-3.03%-13.92%
Medtronic PLC stock logo
MDT
Medtronic
+1.23%+1.43%+5.08%-1.39%+10.85%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+0.82%-1.07%-3.28%+1.56%-51.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.8879 of 5 stars
2.43.04.24.52.92.52.5
DexCom, Inc. stock logo
DXCM
DexCom
4.8828 of 5 stars
3.55.00.04.72.82.51.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9816 of 5 stars
4.44.03.34.02.81.71.9
Medtronic PLC stock logo
MDT
Medtronic
4.8473 of 5 stars
3.33.03.34.02.91.71.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.6251 of 5 stars
4.15.02.50.01.80.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.76
Moderate Buy$142.615.03% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5016.78% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.75
Moderate Buy$1,011.6129.07% Upside
Medtronic PLC stock logo
MDT
Medtronic
2.63
Moderate Buy$97.8712.41% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.27
Hold$112.0063.75% Upside

Current Analyst Ratings Breakdown

Latest DXCM, MDT, NVO, ABT, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Medtronic PLC stock logo
MDT
Medtronic
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
6/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$936.00
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$143.00
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
6/16/2025
Medtronic PLC stock logo
MDT
Medtronic
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025
Medtronic PLC stock logo
MDT
Medtronic
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$110.00
6/6/2025
Medtronic PLC stock logo
MDT
Medtronic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.63$6.65 per share20.41$27.62 per share4.92
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B8.20$2.20 per share38.41$5.38 per share15.68
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.49$14.39 per share54.48$15.03 per share52.15
Medtronic PLC stock logo
MDT
Medtronic
$33.54B3.33$7.84 per share11.10$37.62 per share2.31
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B7.25$3.89 per share17.56$4.66 per share14.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.6423.702.5531.89%19.01%10.82%7/17/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3462.9434.291.8412.90%30.05%10.00%7/24/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2963.7725.191.1322.67%85.51%15.74%8/7/2025 (Estimated)
Medtronic PLC stock logo
MDT
Medtronic
$4.66B$3.6224.0514.932.3213.90%14.54%7.83%8/19/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.3820.2414.681.2234.52%80.94%24.23%8/6/2025 (Estimated)

Latest DXCM, MDT, NVO, ABT, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.45N/AN/AN/A$1.13 billionN/A
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.25N/AN/AN/A$11.01 billionN/A
5/21/2025Q4 2025
Medtronic PLC stock logo
MDT
Medtronic
$1.58$1.62+$0.04$0.82$8.81 billion$8.93 billion
5/7/2025Q1 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92$0.92N/A$0.92N/A$11.87 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.74%N/A30.61%54 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.77%N/A48.82%11 Years
Medtronic PLC stock logo
MDT
Medtronic
$2.843.26%N/A78.45%49 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.642.40%N/A48.52%N/A

Latest DXCM, MDT, NVO, ABT, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
5/21/2025
Medtronic PLC stock logo
MDT
Medtronic
quarterly$0.713.3%6/27/20256/27/20257/11/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Medtronic PLC stock logo
MDT
Medtronic
0.53
1.85
1.42
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.70
0.74
0.56

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Medtronic PLC stock logo
MDT
Medtronic
82.06%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Medtronic PLC stock logo
MDT
Medtronic
0.20%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.41 millionOptionable
Medtronic PLC stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable

Recent News About These Companies

7 Killer European Stocks To Buy In July
Futuristic laboratory, doctor or scientist holding glass tube, molecular and DNA structure, genetic research human biology and pharmaceutical technology, medical,science,development biological system — Photo
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (NVO)
...
6 International Stocks To buy in July

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$135.78 +1.40 (+1.04%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

DexCom stock logo

DexCom NASDAQ:DXCM

$84.35 -2.94 (-3.37%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$783.78 +4.26 (+0.55%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medtronic stock logo

Medtronic NYSE:MDT

$87.07 -0.10 (-0.12%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$68.40 -0.62 (-0.90%)
As of 09:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.